Background
==========

Cervical cancer is the second most common cancer in women worldwide \[[@B1]\], affecting 500,000 women annually and resulting in more than 250,000 deaths \[[@B2]\]. In Singapore, despite decreasing incidence of cervical cancer as a result of regular cytological screening, it remains a common gynaecological cancer \[[@B3]\], with 200 cases and about 100 deaths annually \[[@B3],[@B4]\].

Human papillomavirus (HPV) infection is the main cause of cervical cancer. There are more than 150 different strains of HPV but only about 15 are high-risk oncogenic strains for cervical cancer. Of these, HPV types 16 and 18 account for about 70% of all cervical cancer cases, while the other oncogenic strains account for the rest \[[@B5]-[@B7]\]. Two prophylactic HPV vaccines, a bivalent vaccine which targets HPV 16/18, and a quadrivalent vaccine which targets 6/11/16/18, are widely available. Both vaccines have shown to be highly effective in clinical trials and economic studies of HPV vaccines have found them to be cost-effective in various countries \[[@B8]\]. As such, many countries are considering universal vaccination of women with the HPV vaccine.

Before any universal vaccine implementation, it is important for policymakers to understand the long-term benefits (beyond the time horizon of clinical trials) of the vaccine by using mathematical modelling in a decision-analytic framework \[[@B9]-[@B17]\]. Extending previous studies of HPV vaccination, we compare the status quo of cervical cancer screening only and vaccination with a quadrivalent or bivalent vaccine in addition to baseline screening. This allowed us to determine the cost-effectiveness of vaccination over the current screening practices, and the incremental cost-effectiveness of one vaccine over the other.

Methods
=======

We developed a deterministic Markov state-transition model based on the natural history of HPV infection and cervical cancer in the tropical South-East Asian city-state Singapore (Figures [1](#F1){ref-type="fig"}). We assumed that the natural history is relatively long, therefore the cycles were annual \[[@B18],[@B19]\]. The model was performed on a hypothetical cohort of women in Singapore who turned 12 years old in 2008, which is the typical age of HPV vaccination. This amounted to a mid-year female population of 25,000 \[[@B20]\] and the model followed this cohort until death - 88 cycles, assumed to correspond to the time needed until everyone has died. We assumed that sexual activity and hence HPV infection only occurred after age 12.

![Markov model for the history of cervical cancer](1471-2458-11-203-1){#F1}

Life expectancies and annual mortality rates for the cohort were obtained from the Singapore Department of Statistics \[[@B20]\]. For the input variables (Table [1](#T1){ref-type="table"}) \[[@B4],[@B18]-[@B29]\], we obtained data from local sources where available, including disease incidence and costs of interventions and outcomes. Most studies on disease evolution and transition between different disease states were performed by a few large international studies - we therefore relied on these to obtain input parameters. The variables were calibrated to the local setting based on local incidence data.

###### 

Vaccination, screening, cost parameters and transition probabilities

  Parameters                                                  Base case       Ranges                                        Source
  ----------------------------------------------------------- --------------- --------------------------------------------- -----------------------------------
  **Vaccination**                                                                                                           
  Cohort size                                                 25,000                                                        \[[@B20]\]
  Vaccine coverage                                            100%                                                          Assumption
  Age at vaccination                                          12                                                            
  Vaccine efficacy\* - bivalent vaccine                       87.2%           70%-95%                                       \[[@B21],[@B22]\]
  Vaccine efficacy\* - quadrivalent vaccine                   78.8%           70%-95%                                       \[[@B23]\]
  Duration of efficacy                                        Lifetime        5 years to lifetime                           Assumption
  Vaccine waning + booster                                    None            5, 10, 20 years                               Assumption
                                                                                                                            
  **Screening**                                                                                                             
  Screening age range                                         25-65                                                         \[[@B4]\]
  Screening interval                                          every 3 years                                                 \[[@B4]\]
  Percentage screened per year                                17%             10-20                                         Estimated
  Cytology sensitivity to detect CIN1                         0.58            none                                          \[[@B18],[@B19]\]
  Cytology sensitivity to detect CIN2/3                       0.61            none                                          \[[@B18],[@B19]\]
  Compliance to CIN1 treatment                                75%             50%-100%                                      Assumption
  Compliance to CIN2/3 treatment                              75%             50%-100%                                      Assumption
                                                                                                                            
  **Cancer detection rate**                                   *Low*           *High*                                        
  Probability Of symptons CC1                                 0.075           0.185                                         
  Probability Of symptons CC2                                 0.113           0.3                                           
  Probability Of symptons CC3                                 0.3             0.75                                          \[[@B24],[@B25]\]
  Probability Of symptons CC4                                 0.45            0.8                                           
                                                                                                                            
  **Cost, SGD\$ (2008)**                                                      *(-20%/+50%) except vaccine cost (200-400)*   
  Vaccine cost per vaccinated woman, bivalent vaccine \#      400                                                           
  Vaccine cost per vaccinated woman, quadrivalent vaccine\#   400                                                           Assumption
  Cytology test\^                                             40                                                            
  Colposcopy and Biopsy\^                                     207                                                           
  CIN 1 treatment                                             1,105                                                         
  CIN 2/3 treatment                                           1,480                                                         
  Stage 1 Cancer treatment cost                               9,388                                                         Singapore public sector hospitals
  Stage 2 Cancer treatment cost                               9,765                                                         
  Stage 3 Cancer treatment cost                               9,765                                                         
  Stage 4 Cancer treatment cost                               11,047                                                        
  Genital warts                                               750                                                           
                                                                                                                            
  **Discounting**                                                                                                           
  Costs, Outcomes                                             3%, 3%          (0%-5%)                                       Assumption
                                                                                                                            
  **Transition Probabilities**                                                                                              
  Well to HPV                                                 0.05            0-0.2                                         
  HPV to clearance                                            0.4             0.29-0.55                                     
  HPV to CIN1                                                 0.05            0.014-0.14                                    \[[@B18],[@B19],[@B26]\]
  CIN1 clearance                                              0.4             0.24-0.5                                      
  CIN1 to CIN2/3                                              0.09            0.02-0.32                                     
  CIN2/3 clearance                                            0.25            0.01-0.45                                     
  CIN2/3 to persistent CIN2/3                                 0.11            0.03-0.20                                     
  Persistent CIN2/3 to Cancer stage 1                         0.05            0.001-0.15                                    
  Cancer stage 1 to Cancer stage 2                            0.22            0.11-0.4                                      
  Cancer 1 to cancer cured                                    0.84            0.63-0.98                                     
  Cancer stage 1 to Cancer stage 3                            0.24            0.12-0.5                                      
  Cancer 2 to cancer cured                                    0.66            0.49-0.83                                     
  Cancer stage 3 to Cancer stage 4                            0.24            0.12-0.8                                      
  Cancer 3 to cancer cured                                    0.38            0.28-0.48                                     \[[@B21],[@B22],[@B24]-[@B26]\]
  Cancer 4 to cancer cured                                    0.11            0.08-0.14                                     
  Detected CIN1 to well                                       0.9             0.8-1                                         
  Detected CIN1 to Detected CIN2/3                            0.09            0.02-0.32                                     
  Detected CIN2/3 to Well                                     0.9             0.8-1                                         
  Detected CIN2/3 to Detected PCIN2/3                         0.11            0.03-0.20                                     
  Detected PCIN2/3 to Cancer 1                                0.05            0.001-0.15                                    
  Mortality of cervical cancer                                0.11                                                          
                                                                                                                            
  **Cervical Warts**                                                                                                        
  Effectiveness of vaccination against warts                  0.90                                                          \[[@B27],[@B28]\]
  Cost of treatment                                           750                                                           
  Well to low risk HPV                                        0.050                                                         
  Low risk HPV to well                                        0.500                                                         
  Low risk HPV to CIN1 low risk                               0.036                                                         
  Low risk HPV to warts                                       0.027                                                         
  Warts to well                                               0.875                                                         
  CIN1 low risk to well                                       0.500                                                         
  CIN1 low risk to detected CIN 1 low risk                    0.099                                                         
  Detected CIN 1 low risk to well                             0.950                                                         
                                                                                                                            
  **QALYs**                                                                                                                 
  Disease free                                                1                                                             
  Genital warts                                               0.96            0.91-0.99                                     \[[@B10],[@B25],[@B29]\]
  Detected CIN                                                0.89            0.84-0.94                                     
  Cancer detected                                                                                                           
    Stage I                                                   0.65            0.49-0.81                                     
    Stage II                                                  0.56            0.42-0.70                                     
    Stage III                                                 0.56            0.42-0.70                                     
    Stage IV                                                  0.48            0.36-0.60                                     
  Cancer cured                                                0.94                                                          

\*Calculated, refer to Table 1b.

^\#^including costs of implementing, administration and support for vaccination programme

\^including admininistrative cost & patient costs

Transition probabilities
------------------------

HPV infection progresses to cervical intraepithelial neoplasia (CIN), the precursor of cervical cancer. The usual progression is from CIN 1 to CIN 2, CIN 3, and persistent forms of the latter 2 CIN stages. CIN 2,3 is grouped together due to similar outcomes and management, while the persistent forms are direct precursors of cervical cancer. Cervical cancers are divided into 4 prognostic stages 1 to 4. Each progressive stage is associated with poorer prognosis, lower treatment success rates, and higher recurrence and relapse rates. The transition probabilities for disease progression were obtained from previously published sources (Table [1](#T1){ref-type="table"}). To account for uncertainty, we performed wide sensitivity analyses.

Screening
---------

In Singapore, recommended screening for cervical cancer starts at age 25 years for women who have ever had sexual intercourse and at 3 yearly intervals if previous smears were negative, until the age of 69 if all smears are negative. In 2004, a survey showed that across all age groups, only 52% of women had their Pap smear done in the last 3 years, but most women did not undergo regular screening every 3 years \[[@B4]\]. We therefore assumed that Singaporean women would on average start screening at 25 years of age, and 17% of the cohort would undergo screening each year.

We assumed that the sensitivity of PAP smears were 58% for CIN 1 and 61% for CIN2,3 \[[@B30],[@B31]\]. If a smear is abnormal, further tests including colposcopy and if necessary biopsy are introduced as per local abnormal pap smear guidelines \[[@B41]\], and treatment performed as clinically indicated. We also assumed that once positive, all CIN states would be confirmed by colposcopy and biopsy, and 75% of CIN1 and 75% of CIN2, 3 cases would comply to treatment with an efficacy of 90% \[[@B32]\].

Treatment
---------

For CIN, the chance of cure is almost 100% and we assumed a mean cost of treatment for the various CIN stages. For cervical cancer, the chance of cure depends on the cancer stage, while the treatment cost depends on the treatment type. We also determined the chance of symptoms occurring which would lead to early detection and treatment. We modeled these outcomes and costs based on local data obtained from hospitals. As local data on survival rates together with disease transition probabilities were not available, and overall survival rates in Singapore were comparable to developed countries \[[@B42]\], we used available cancer survival rates from similar developed countries \[[@B21],[@B22]\]. These survival rates were annualized across 5 years to determine overall cure rates for each year - we assumed that those who survive beyond 5 years were cured. Once cancer was detected, we assumed that all individuals would undergo treatment. We did not model outcomes of treatment as individual state transitions but attributed an overall cost to each state.

Vaccination
-----------

In Singapore, the quadrivalent and bivalent vaccines have been licensed since 2006 and 2007 respectively. Vaccination remains voluntary, and privately funded individually. To compare between the vaccines, we assumed that the bivalent vaccine has a higher efficacy against other non-16/18 high-risk HPV types compared with the quadrivalent vaccine \[[@B32]\] using a technique described by Debicki et al \[[@B25]\] and shown in Table [2](#T2){ref-type="table"}. However, the quadrivalent vaccine has additional protection against other low-risk HPV-types that cause genital warts and CIN 1 - the bivalent vaccine is assumed to have no such protection.

###### 

Details of efficacy calculations

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                           Source
  ------------------------------------------------------------------------------------ --------------- ------------------- ----------------------------------------
                                                                                       **Bivalent**\   **Quadrivalent**\   
                                                                                       **vaccine**     **vaccine**         

                                                                                                                           

  **Reduction in the probability of HPV infection**                                                                        

  Assumed proportion of HPV 16/18 in cervical cancer, A                                74.9%           74.9%               \[[@B7]\]

  Vaccine efficacy-percent reduction in HPV 16/18 persistent infections, B             95.0%           95.0%               \[[@B23],[@B27],[@B28],[@B32]-[@B40]\]

  Assumed proportion of other high risk HPV in cervical cancer, C                      23.4%           23.4%               \[[@B7]\]

  Vaccine efficacy-percent reduction in other high risk HPV persistent infections, D   68.4%           32.5%               \[[@B30]-[@B32]\]

  Calculated reduction in the probability of HPV infection (AxB)+(CxD)                 87.2%           78.8%               

                                                                                                                           

  **Corection factor for CIN1**                                                                                            

  Percent of HPV 1618 in CIN1 cases which are caused by oncogenic HPV, E               37.0%                               

  Correction factor for CIN1, A-E                                                      37.9%                               

                                                                                                                           

  **Corection factor for CIN2/3**                                                                                          

  Percent of HPV 1618 in CIN2/3 cases which are caused by oncogenic HPV, F             52.0%                               

  Correction factor for CIN2/3 A-F                                                     22.9%                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

Based on recent studies, the range of protection for non-16/18 oncogenic HPV types are between 53.0% and 68.2% for the bivalent vaccine \[[@B23],[@B33]\] and 32.5% for the quadrivalent vaccine \[[@B21]\]. The overall effectiveness for the quadrivalent vaccine has been shown to be about 75% \[[@B34]\]. In addition, the quadrivalent vaccine has a 90% protection against HPV-types that cause genital warts \[[@B27],[@B28]\]

Base case vaccine characteristics are assumed as follows: (1) proportion of individuals protected following immunization is 100%; (2) vaccine duration is life-long; (3) effectiveness of both vaccines against HPV types 16/18 are similar at 95% \[[@B23],[@B33]-[@B40]\]; (4) to create fair competition, we assumed that the prices of both vaccines were equivalent and includes all vaccination costs; (5) we did not include therapeutic benefits to vaccinated patients already infected and assumed that the natural disease history is unaltered; (6) we assumed that all girls based on the coverage rate would receive the full vaccine course and be immunized after 1 year. We performed sensitivity analyses on these assumptions.

CIN State Adjustments
---------------------

For the CIN states, we had to determine the actual proportion of CIN cases that are reduced by vaccination, as not all CIN states are affected by vaccination as compared to cancer. This is to allow for the reduction proportion to be accurate as this will influence the costs of the different strategies. We used a correction method well described by Debicki et al \[[@B25]\] where we determined the proportion of CIN 1 and CIN2/3 cases that were caused by non-oncogenic viruses in the no vaccine strategy, and added these numbers to those obtained for oncogenic viruses in the vaccination strategy (Table [2](#T2){ref-type="table"}).

Genital Warts
-------------

Genital warts are another manifestation of HPV infection caused by non-oncogenic HPV viruses. Low-oncogenic-risk HPV-6/11 is responsible for \>95% percent of genital warts \[[@B43],[@B44]\]. Genital warts cause superficial symptoms but do not result in cancer, and are therefore a separate outcome of HPV infection.

The model for the development of genital warts is shown in Figure [2](#F2){ref-type="fig"}. We assumed that low-oncogenic-risk HPV types can either cause clinical genital warts or CIN 1. Clinical genital warts would be identified clinically and treated. CIN 1 would be detected through the normal screening process and we assumed would be indistinguishable from CIN 1 caused by oncogenic types. A reduction in CIN 1 caused by low-oncogenic-risk HPV types would contribute to the overall reduction in CIN 1 incidence \[[@B45]\].

![Markov model for the history of genital warts](1471-2458-11-203-2){#F2}

Costs, Utility, and discounting
-------------------------------

Costs of the various interventions and outcomes were obtained from patients with HPV infection, CIN states, and cervical cancer diagnosed in 2004 across public sector hospitals in Singapore (SK Tay, unpublished data). All medical services were traced and costs collected from hospital finance data for the following 5 years or until death, and averaged across all patients. We performed the analysis starting from the year 2008 and all interventions according to technology available in 2008. We adopted the health services perspective and included all direct medical costs and benefits. Vaccination cost includes the vaccine cost and related administrative fees. All costs are represented in 2008 Singapore dollars (2008 exchange rate, USD1: SGD1.416).

For the Quality-Adjusted Life Years (QALYs) calculations, the utility values were obtained from other developed countries as similar data was not available locally (Table [1a](#T1){ref-type="table"}). Utility for each health state, which ranged from 1 which corresponded to complete health to 0 for death, were multiplied by the time spent in each state. Genital warts and detected CIN (colposcopy treatment) was given utility values of 0.96 and 0.89 respectively \[[@B29]\]. Quality values for various detected cancer stages differed depending on the cancer stage, while cured cancer was slightly less than complete health \[[@B10],[@B25]\].

Since the model ran over a long time-frame, costs and benefits were translated into present values using a discount factor \[[@B46]-[@B49]\]. Health outcomes and costs were discounted at 3% per annum, similar to previous local economic evaluations.

Analyses
--------

The model was run using Excel spreadsheets (Microsoft Corp, Redmond, WA) and \@Risk (Palisade, Newfield, NY) simulation add-in. We performed cost-benefit analysis using the costs per life-year saved with individual economic value calculated from the net present value of future annual earnings (earnings-equivalent for the elderly), adjusted for age \[[@B50]\]. We also performed cost-effectiveness analyses; and cost-utility analyses as not all negative health outcomes resulted in death. The incremental cost-effectiveness ratio (ICER) would be acceptable if it is below the per-capita gross domestic product (GDP) for the population. The per-capita GDP for Singapore in 2008 was \$53,192.

All parameters were subject to sensitivity analysis to determine which input variables were most important in determining the final strategy. We performed one-way and two-way sensitivity analyses on vaccination and transition parameters to determine the impact of changes in input variables. This allowed us to determine which parameters had the highest influence on the outcome, and would be priority areas for intervention.

Results
=======

Base case analysis
------------------

Table [3](#T3){ref-type="table"} reports the base-case results of estimated cases, non-discounted and discounted total costs, life-years, and QALYs. The model estimates that approximately 86% of cervical cancer, 86% of deaths from cancer, and 47% of CIN 1, 65% of CIN 2/3, and 86% of persistent CIN 2/3 cases could be prevented by the bivalent vaccine vaccination. The quadrivalent vaccine avoids these cases by 2-9% less than the bivalent vaccine. However, the quadrivalent vaccine reduces genital warts cases by 89%. Vaccination with the bivalent or quadrivalent vaccine yielded 634 and 570 respectively more life years than screening alone.

###### 

Summary of estimated cases, non-discounted and discounted total costs and life-years of a single age-cohort (n = 25,000) of 12 year old girls

                                                           Screening only   Bivalent\*   Quadrivalent\*
  ----------------- -------------------------------------- ---------------- ------------ ----------------
  Cases                                                                                  
                    Cervical cancer                        229              32           53
                    Deaths from cervical cancer            144              20           33
                    CIN Persistent 2n3 detected            2,073            294          480
                    CIN 2n3 detected                       382              135          168
                    CIN 1 detected                         2,109            1,127        1,293
                    Genital warts                          4,126            4,126        447
                                                                                         
  NON-DISCOUNTED                                                                         
  Total costs                                              21,150,496       25,020,340   22,822,396
                    Vaccine costs                          \-               10,000,000   10,000,000
                    Screening costs                        11,006,014       9,949,324    10,078,234
                    CIN1 treatment costs                   2,330,522        1,245,203    1,292,796
                    CIN 2 & 3 treatment costs              564,776          199,475      247,908
                    CIN Persistent 2 & 3 treatment costs   3,067,301        435,141      710,367
                    Genital warts treatment costs          3,094,714        3,094,714    335,580
                    Cervical cancer treatment costs        1,087,169        96,483       157,511
                                                                                         
  Life-years (LY)                                          1,692,651        1,695,651    1,695,338
  QALYs                                                    1,717,089        1,720,571    1,720,299
                                                                                         
  DISCOUNTED                                                                             
  Total costs                                              6,880,106        15,034,926   14,210,399
  Life-years (LY)                                          711,164          711,800      711,734
  QALYs                                                    735,991          736,775      736,784

\*In addition to screening

From the cost-benefit analysis, the incremental savings is \$8.23 m with the quadrivalent vaccine and \$9.47 m with the bivalent vaccine, or an advantage of \$1.24 m for the bivalent over the quadrivalent vaccine. For the cost-effectiveness analysis, the cost per life year saved for the quadrivalent vaccine compared to no vaccine was \$12,866, compared to \$12,827 for the bivalent vaccine. Comparing the bivalent to the quadrivalent vaccine, the ICER is \$12,488, showing that the bivalent vaccine saves more lives for the cost. However, the cost per QALY saved for the quadrivalent vaccine compared to no vaccine was \$9,071, while it was \$10,392 for the bivalent vaccine, with the quadrivalent vaccine dominating the bivalent vaccine due to the additional QALY effect from reduction in genital warts.

Sensitivity analysis
--------------------

For the sensitivity analyses, we compared 3 different outcomes - the quadrivalent vaccine to screening alone, the bivalent vaccine to screening alone and the bivalent vaccine to the quadrivalent vaccine. Table [4](#T4){ref-type="table"} shows selected sensitivity analyses results. Decreasing vaccine coverage while keeping vaccination costs constant (assuming that vaccine purchases are sunk costs) increased the ICER and decreases cost-benefit across the board, especially at vaccine coverage levels ≤40% where vaccination is not cost-effective. If vaccination costs can be capped to only those who receive vaccination, then either vaccine remains cost effective even at 20% vaccination levels.

###### 

Sensitivity analysis for the imput parameters on ICER and Cost-Benefit

  Parameters                                                                                     ICER (SGD/LY saved), discounted   ICER (SGD/QALY saved), discounted   Cost Benefit Analysis (million SGD), discounted                                                 
  ---------------------------------------------------------------------------------------------- --------------------------------- ----------------------------------- ------------------------------------------------- -------- -------- --------- -------- -------- -------
  Base case                                                                                      12,866                            12,827                              12,488                                            9,071    10,392   Dom       8.23     9.47     1.24
                                                                                                                                                                                                                                                                       
  Vaccine coverage (base:100%) - assuming vaccine purchase costs for the cohort are sunk costs                                                                                                                                                                         
   20%                                                                                           86,397                            83,454                              56,178                                            61,804   67,631   Dom       -6.25    -6.57    -0.33
   40%                                                                                           40,444                            39,322                              29,109                                            28,847   31,864   Dom       -2.72    -2.75    -0.03
   60%                                                                                           25,124                            24,607                              19,981                                            17,861   19,938   Dom       0.92     1.21     0.29
   80%                                                                                           17,464                            17,246                              15,337                                            12,367   13,973   Dom       4.67     5.23     0.63
                                                                                                                                                                                                                                                                       
  Vaccine coverage (base:100%) - assuming vaccine costs are as consumed                                                                                                                                                                                                
   20%                                                                                           11,524                            15,873                              56,178                                            8,059    12,818   Dom       1.75     1.43     -0.33
   40%                                                                                           12,804                            14,417                              29,109                                            9,010    11,668   Dom       3.38     3.25     -0.03
   60%                                                                                           13,034                            13,733                              19,981                                            9,166    10,727   Dom       4,92     5.21     0.29
   80%                                                                                           13,003                            13,241                              15,337                                            9,185    11,122   Dom       6,67     7.3      0.63
                                                                                                                                                                                                                                                                       
  Vaccine efficacy (Bivalent base: 88.3%, Quadrivalent base: 79.4%)                                                                                                                                                                                                    
   70%                                                                                           15,008                            17,237                              Dom                                               10,369   13,894   Dom       6.43     5.31     -1.11
   90%                                                                                           10,863                            12,326                              Dom                                               7,733    9,932    Dom       11.13    10.17    -0.96
                                                                                                                                                                                                                                                                       
  Vaccination costs (base: SGD\$400 for both)                                                                                                                                                                                                                          
   Decrease to SGD\$300 for both                                                                 8,521                             8,942                               12,572                                            5,922    7,205    Dom       10.96    11.96    1
   Decrease to SGD\$200 for both,                                                                4,109                             4,988                               12,572                                            2,775    4,019    Dom       13.46    14.46    1
   Decrease to SGD\$100 for both                                                                 Dom                               1,034                               12,572                                            Dom      833      Dom       15.96    16.96    1
                                                                                                                                                                                                                                                                       
  Booster (base: none)                                                                                                                                                                                                                                                 
   5 years                                                                                       91,149                            83,707                              19,486                                            67,830   70,487   Dom       -36.07   -35.52   0.54
   10 years                                                                                      47,045                            43,778                              15,584                                            36,192   38,134   Dom       -10.94   -10.14   0.8
   20 years                                                                                      27,321                            26,048                              15,067                                            19,483   21,093   Dom       0.3      1.13     0.84
                                                                                                                                                                                                                                                                       
  Screening coverage rate (base: 17%)                                                                                                                                                                                                                                  
   10%                                                                                           12,424                            12,398                              12,171                                            9,120    10,409   Dom       9.2      10.29    1.08
   25%                                                                                           13,670                            13,558                              12,593                                            9,199    10,552   Dom       7.68     8.63     0.95
   40%                                                                                           15,200                            14,845                              11,783                                            9,628    10,977   Dom       6.43     7.35     0.92
  Effectiveness against viral warts                                                                                                                                                                                                                                    
   70%                                                                                           13,348                            12,827                              8,996                                             9,665    10,392   57,447    8.23     9.46     1.23
   80%                                                                                           13,143                            12,827                              10,768                                            9,366    10,392   640,633   8.35     9.46     1.11
   100%                                                                                          12,721                            12,827                              14,408                                            8,777    10,392   Dom       8.59     9.46     0.86

Dom = Dominated by quadrivalent vaccine

Lowering the overall vaccine efficacy increases ICER and decreases cost-benefit for both vaccination strategies compared to no vaccination, but vaccination still remains cost-effective even if no cross-reactivity against low-risk HPV types is present. In the latter scenario, the quadrivalent vaccine dominates the bivalent vaccine even for the additional cost per life year saved, due to the additional reduction on genital warts.

Decreasing vaccination costs for both vaccines decreases the overall ICER and increases the cost-benefit of the vaccination strategy. Conversely, overall ICER for all comparisons increases and cost-benefit decreases when vaccine waning and administering a booster in the future are considered, although the vaccination strategies are still cost-effective up to 10 yearly boosters.

Changing the cervical cancer screening rates through pap smears affects the outcomes - increasing screening coverage rates increases ICER and decreases cost-benefit for vaccination due to the higher rates of early detection of CIN states which can be treated before they develop cancer. Increasing screening coverage also decreases the cost per life year saved for the bivalent vaccine compared to the quadrivalent vaccine because screening reduces CIN cases and therefore the advantage that the quadrivalent vaccine has in reducing the number of CIN cases due to non-oncogenic HPV.

The ICER for the quadrivalent vaccine vs. no vaccine increases with reduced effectiveness of the quadrivalent vaccine against genital warts. At 100% effectiveness the quadrivalent vaccine vs. no vaccine is more cost-effective compared to the bivalent vaccine vs. no vaccine across all 3 measures. Changing the sensitivity of the pap- smear tests, the compliance to treatment, or the cost of the interventions does not change the outcome substantially - vaccination remains cost-effective and the bivalent vaccine remains the more cost-beneficial strategy compared to the quadrivalent vaccine, and more-cost effective per life year saved. However, when using cost-per QALY saved, the quadrivalent vaccine dominates the bivalent vaccine across the board due to the additional QALYs saved from reducing genital warts.

The results of the one-way sensitivity analysis on ICER are shown in Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}. It is evident that the primary outcome is most affected by the vaccine effectiveness and the percentage of vaccine coverage. This means that vaccine parameters are the most important factors in the overall outcomes. The probability of infection with HPV, the probability of conversion from HPV to CIN1, and the transition probabilities between the CIN states and back to the well state also have some impact on the outcome. This is likely due to the importance of these parameters on the number of CIN cases that require treatment, and the eventual number of cancer cases. This also means that prevention of HPV infection and CIN is important to reduce the impact from the disease.
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![One-way sensitivity analysis tornado diagrams for the bivalent vaccine](1471-2458-11-203-4){#F4}

Discussion
==========

During the last few decades, cervical cytology programmes have demonstrated their usefulness in reducing cervical cancer mortality and morbidity in many developed countries. However, it is a well-established fact that to be successful in population-based cervical screening, the coverage of the population screened must be adequate and this has often proved difficult to achieve. Although the incidence has declined over the years, cervical cancer, which is a preventable cancer, is still a common gynecological cancer in Singapore. With the global arrival of HPV vaccines, vaccination may be a successful complement to screening and decision on adoption of HPV vaccination will need to be made across individual countries.

The results of this study conclusively shows that HPV vaccination is a cost effective strategy at the population level, as the ICERs across most vaccination strategies were much lower than the per-capita GDP for Singapore, and the vaccine strategies were more cost-beneficial under a wide range of circumstances. This is similar to a recent study in Taiwan which showed the cost-effectiveness of universal vaccination of adolescent girls \[[@B51]\].

As a base case, the cost per life year saved for the bivalent vaccine was slightly lower compared to the quadrivalent vaccine, and the cost-benefit higher. At the same time, the cost per QALY saved is slightly lower for the quadrivalent vaccine compared to the bivalent vaccine. This is because the quadrivalent vaccine resulted in benefits from reduction in genital warts and CIN, but the bivalent vaccine increased life-years saved. Policy makers will therefore have to consider these factors (higher reduction in QALY versus more lives saved) in choosing between the 2 vaccines, but either option is much better than no vaccination at all.

The bivalent vaccine is most cost-beneficial at higher vaccine coverage rates of \>40%, while the quadrivalent vaccine is more cost-effective and cost-beneficial at lower coverage rates as the number of lives saved are reduced. The quadrivalent vaccine also dominates the bivalent vaccine in the absence of cross-reactivity against non-16/18 oncogenic HPV types, due to the additional reduction on genital warts. This is similar to another study in Ireland which shows that the quadrivalent vaccine was more cost-effective assuming both vaccines have similarly high protective efficacy against HPV \[[@B29]\].

Of interest, if vaccine purchases are a priori and are sunk costs, the ICER increases substantially for both vaccines as vaccine coverage decreases, and cost-benefit decreases. Under this assumption, vaccine coverage of ≤40% would render vaccination not cost-effectiveness as an overall strategy. It is therefore important for policy makers rolling out universal vaccination strategies with stockpiled vaccines to ensure sufficient vaccine uptake to maintain high societal economic benefit, or to purchase vaccines on an as required basis based on vaccination uptake.

In addition, the waning of immunity and additional vaccinations contribute substantial to the vaccination costs. Boosters at intervals of once every 20 years still maintain the cost-effectiveness of vaccination. However, more frequent boosters of less than 10 years render vaccination a non-cost-effective strategy. Waning of immunity results in costs far greater compared to the absence of cross-protection to non-16/18 oncogenic HPV types or to genital warts. It is therefore more important for vaccine manufacturers to increase the efficacy of their vaccines in terms of long-term immunity.

This study does not take into account the dynamics of viral transmission and thus underestimating the impact of herd immunity. Transmission models that accounted for herd immunity suggest that vaccination and screening strategy would be much more attractive compared to screening-only - Chesson et al \[[@B9]\] further demonstrated that herd immunity could reduce ICER by 37.9%. In addition, women who adhere to previous cervical screening tests may have better compliance with subsequent tests, but with the lack of information in the local context, we did not perform individual-based modelling. Also, the model does not take into consideration the potential reduction of other HPV-related cancers like adenocarcinoma of the cervix, vulvar carcinoma or laryngeal papillomatosis. Indirect costs such as absence of work or transportation costs for patients with cervical cancer are also excluded. Given that this study did not include herd immunity effects, we did not study the outcomes of vaccinating boys or optimal catch-up strategies, and we did not consider catch up vaccination, which could increase the immediate benefits of vaccination programs.

Conclusions
===========

We demonstrate that vaccination of adolescent girls, in addition to current cytology-based screening, is a cost-effective use of healthcare resources. The bivalent vaccine saves more lives compared to the quadrivalent vaccine, while the quadrivalent vaccine has lower cost per QALYs saved compared to the bivalent vaccine. The main advantage of vaccination will be to reduce cervical cancer mortality but the full benefits of vaccination will be observed 10-20 years after its introduction. Further studies should focus on quantifying the duration of vaccine protection, and use dynamic models to examine the efficiencies of different screening and vaccine strategies in reducing HPV-related disease. Studies should also focus on optimal synergies between screening and vaccination and on affordability and equity in delivery.
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